Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years.
Allogeneic hematopoietic stem cell transplantation
Functional domains
Geriatric assessment
Transplantation outcome
Treatment-related mortality
Journal
Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
23
02
2022
revised:
10
05
2022
accepted:
11
05
2022
pubmed:
21
5
2022
medline:
4
8
2022
entrez:
20
5
2022
Statut:
ppublish
Résumé
Allogeneic hematopoietic stem cell transplantation (HCT) is a potentially curative treatment for both malignant and nonmalignant hematologic diseases; however, reported rates of treatment-related mortality approach 30%. Outcomes are worse in patients who begin HCT with functional impairments. To detect such impairments, a geriatric assessment (GA) is recommended in adults age ≥65 years. Younger HCT candidates also may be impaired because of chemotherapy regimens pre-HCT. Therefore, we hypothesized that GA can be beneficial for adult patients of all ages and subsequently created a clinical pretransplantation optimization program to assess all HCT candidates using a modified GA. One-hundred fifty-seven patients were evaluated in 4 functional domains- physical, cognitive, nutritional, and psychological-at 2 time points prior to HCT-new patient evaluation (NPE) and sign-off (SO)-between October 2017 and January 2020. At NPE, 80.9% of the patients had at least 1 domain with a functional impairment, and physical (P = .006), cognitive (P = .04), and psychological (P = .04) impairments were associated with an increased likelihood of not proceeding to HCT. In addition, patients age 18 to 39 years were more likely than older patients to have a physical function impairment (P = .001). Between NPE and SO, 51.9% of the patients had resolution of 1 or more impairments, and nutritional impairment at SO was predictive of worse overall survival (P = .01). Our study shows that GA can identify functional impairments in patients of all ages. Early identification of impairments could facilitate referrals to supportive care and resolution of impairments prior to HCT, suggesting that GA could be recommended for HCT candidates of all ages.
Identifiants
pubmed: 35595226
pii: S2666-6367(22)01310-0
doi: 10.1016/j.jtct.2022.05.018
pmc: PMC10042624
mid: NIHMS1874600
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
498.e1-498.e9Subventions
Organisme : NIA NIH HHS
ID : P30 AG028716
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG066388
Pays : United States
Informations de copyright
Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Références
Blood. 2012 Jan 5;119(1):296-307
pubmed: 22010102
J Clin Oncol. 2014 Aug 20;32(24):2595-603
pubmed: 25071125
Neurology. 2009 Nov 24;73(21):1738-45
pubmed: 19933974
J Gerontol A Biol Sci Med Sci. 2011 Jan;66(1):89-96
pubmed: 20861145
J Gerontol. 1994 Mar;49(2):M85-94
pubmed: 8126356
Cancer. 2016 Jan 1;122(1):91-8
pubmed: 26439325
N Engl J Med. 2010 Nov 25;363(22):2091-101
pubmed: 21105791
Haematologica. 2014 Aug;99(8):1373-9
pubmed: 24816237
Cancer. 2017 May 15;123(10):1828-1838
pubmed: 28102896
N Engl J Med. 1994 Nov 10;331(19):1253-8
pubmed: 7935682
Acta Oncol. 1997;36(6):549-64
pubmed: 9408144
Biol Blood Marrow Transplant. 2020 Jan;26(1):189-196
pubmed: 31493541
Curr Anesthesiol Rep. 2017;7(4):340-349
pubmed: 29200973
J Clin Oncol. 2011 Mar 1;29(7):805-13
pubmed: 21220593
Bone Marrow Transplant. 2018 May;53(5):565-575
pubmed: 29330399
Leuk Lymphoma. 2016 Aug;57(8):1807-13
pubmed: 26699199
Am Fam Physician. 2011 Jan 1;83(1):48-56
pubmed: 21888128
Ther Adv Hematol. 2016 Jun;7(3):131-41
pubmed: 27247754
Oncologist. 2015 Apr;20(4):379-85
pubmed: 25765876
J Gen Intern Med. 2016 Oct;31(10):1206-11
pubmed: 27170304
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Semin Oncol. 1995 Aug;22(4):405-11
pubmed: 7638637
J Clin Oncol. 2012 May 20;30(15):1829-34
pubmed: 22508806
J Natl Cancer Inst. 2012 Apr 18;104(8):581-9
pubmed: 22457474
Cancers (Basel). 2018 Jun 04;10(6):
pubmed: 29866998
J Trauma Stress. 2015 Dec;28(6):489-98
pubmed: 26606250
J Clin Oncol. 2010 Jan 20;28(3):380-6
pubmed: 20008637
Proc Inst Med Chic. 1975 Jul-Sep;30(8):256-8
pubmed: 1103123
Oncologist. 2020 Apr;25(4):355-358
pubmed: 32297445
Semin Oncol. 1997 Feb;24(1):114-23
pubmed: 9045297
Geriatr Gerontol Int. 2010 Jul;10(3):225-32
pubmed: 20141536
J Clin Oncol. 2018 Aug 1;36(22):2326-2347
pubmed: 29782209
Biol Blood Marrow Transplant. 2019 Jun;25(6):1218-1224
pubmed: 30708189
J Geriatr Oncol. 2014 Oct 1;5(4):422-30
pubmed: 24835889
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):99-105
pubmed: 27913468
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
JAMA Surg. 2013 Dec;148(12):1132-8
pubmed: 24108317
Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1384-7
pubmed: 9817683
Bone Marrow Transplant. 2013 Oct;48(10):1296-301
pubmed: 23584440
Am Soc Clin Oncol Educ Book. 2016;35:e516-22
pubmed: 27249761
J Clin Oncol. 2011 Sep 1;29(25):3457-65
pubmed: 21810685